News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Mallinckrodt Inc. Signs Distribution Agreement With Amneal Pharmaceuticals


8/20/2013 10:47:38 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

HAZELWOOD, Mo.--(BUSINESS WIRE)--Mallinckrodt (NYSE: MNK) announced today that it has entered into an agreement with Amneal Pharmaceuticals LLC to distribute to addiction treatment centers its Buprenorphine HCl and Naloxone HCl Dihydrate Sublingual Tablets (CIII), a generic version of Suboxone®, manufactured in Amneal’s Hauppauge, New York, facility. The product is a prescription medication indicated for the maintenance treatment of opioid dependence. The contract covers a period of three years, with an option to extend.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES